397 related articles for article (PubMed ID: 16650499)
1. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
Pimentel FL; Bhalla S; Laranjeira L; Guerreiro M
Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
[TBL] [Abstract][Full Text] [Related]
2. Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy.
Novello S; Kielhorn A; Stynes G; Selvaggi G; De Marinis F; Maestri A; Foggi P; Tilden D; Tonato M; Crinò L; Rinaldi M; Migliorino AM; Scagliotti GV;
Lung Cancer; 2005 Jun; 48(3):379-87. PubMed ID: 15893007
[TBL] [Abstract][Full Text] [Related]
3. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe.
Schiller J; Tilden D; Aristides M; Lees M; Kielhorn A; Maniadakis N; Bhalla S
Lung Cancer; 2004 Jan; 43(1):101-12. PubMed ID: 14698544
[TBL] [Abstract][Full Text] [Related]
4. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
5. Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
Reaume MN; Leighl NB; Mittmann N; Coyle D; Hirsh V; Seymour L; Tu D; Shepherd FA; Graham B; Gridelli C; Perrone F; Di Maio M; Bradbury PA; Evans WK
Lung Cancer; 2013 Oct; 82(1):115-20. PubMed ID: 23962449
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
[TBL] [Abstract][Full Text] [Related]
7. Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States.
Lang K; Marciniak MD; Faries D; Stokes M; Buesching D; Earle C; Treat J; Babineaux S; Morissette N; Thompson D
Value Health; 2009 Jun; 12(4):481-8. PubMed ID: 18980633
[TBL] [Abstract][Full Text] [Related]
8. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
Martoni A; Marino A; Sperandi F; Giaquinta S; Di Fabio F; Melotti B; Guaraldi M; Palomba G; Preti P; Petralia A; Artioli F; Picece V; Farris A; Mantovani L
Eur J Cancer; 2005 Jan; 41(1):81-92. PubMed ID: 15617993
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective.
Palmer AJ; Brandt A
Monaldi Arch Chest Dis; 1996 Aug; 51(4):279-88. PubMed ID: 8909011
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
[TBL] [Abstract][Full Text] [Related]
11. Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer.
Rubio-Terrés C; Tisaire JL; Kobina S; Moyano A
Lung Cancer; 2002 Jan; 35(1):81-9. PubMed ID: 11750717
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous non-small-cell lung cancer in Spain.
González García J; Gutiérrez Nicolás F; Nazco Casariego GJ; Valcárcel Nazco C; Batista López JN; Oramas Rodríguez J
Farm Hosp; 2017 Jan; 41(n01):3-13. PubMed ID: 28045649
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer.
Sacristán JA; Kennedy-Martin T; Rosell R; Cardenal F; Antón A; Lomas M; Alberola V; Massuti B; Carrato A; Minshall M
Lung Cancer; 2000 May; 28(2):97-107. PubMed ID: 10717327
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer.
Neymark N; Lianes P; Smit EF; van Meerbeeck JP
Pharmacoeconomics; 2005; 23(11):1155-66. PubMed ID: 16277550
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
[TBL] [Abstract][Full Text] [Related]
16. Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer.
Chisaki Y; Nakamura N; Yano Y
Biol Pharm Bull; 2017; 40(1):73-81. PubMed ID: 28049952
[TBL] [Abstract][Full Text] [Related]
17. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
19. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
Plosker GL; Hurst M
Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
